The latest Business updates from the science industry
by Heather Hobbs
Integra Donates over $35,000 to Support Groundbreaking Breast Cancer Research
Breast cancer is one of the most common forms of cancer facing women worldwide. To help fi ght this disease, Integra launched PIPETGIRL - a limited edition of the PIPETBOY acu 2 pipette controller - in 2015 to support internationally renowned research institutes dedicated to fi nding a cure for breast cancer, donating €10/US$15 from each sale. A number of research institutes have benefi tted since the scheme’s beginning and, as this initiative has now come to a close, Integra is delighted to have awarded the last donation of €15,000 to the National Center for Tumor Diseases (NCT), in Heidelberg, Germany.
NCT Heidelberg is a joint institution, uniting the German Cancer Research Center (DKFZ) and the Heidelberg University Hospital (UKHD), which combines excellent patient care with innovative cancer research under one roof; state-of-the-art research is to be translated as fast as possible into better treatment and prevention strategies. Professor Dr Andreas Schneeweiss, head of the Division
of Gynecologic Oncology at NCT Heidelberg, commented: “This donation will support two innovative programs - CATCH and COGNITION - with the ultimate goal of implementing personalised therapy for breast cancer.”
Lydiane Saucède, Product Manager and Application Specialist at Integra, added: “We’re so pleased to have had this initiative running for four years. Since it’s humble beginning in 2015, we’ve been able to pledge over $35,000 to support cancer research institutes globally and advance research to fi ght breast cancer. We are excited to see how this latest donation will help to fund these groundbreaking programs.”
More information online:
ilmt.co/PL/V1AE 51027pr@reply-direct.com
Acquisition Empowers Approach to Complex Data Management
EU Citizens Offered Access to Online AI Course
Finland ended its tenure as President of the Council of the European Union (July-Dec 2019) by making the free online course series available in all offi cial EU languages starting next year.
“Our investment has three goals: we want to equip EU citizens with digital skills for the future; we wish to increase practical understanding of what artifi cial intelligence is; and, by doing so, we want to give a boost to the digital leadership of Europe,” said Finland’s Minister of Employment, Timo Harakka.
The initiative seeks to meet the challenges posed by the transformation of work and to reinforce the digital leadership of the EU.
“The signifi cance of AI is growing. To make use of it, we need digital skills. Changing labour markets, the transformation of work, digitalisation and intensifying global competition all mean one thing for the EU: we must invest in people,” Harakka continued.
The Elements of AI was successfully launched in Finland in 2018 by the University of Helsinki and local tech company Reaktor. It aims to encourage people to learn the basics of artifi cial intelligence, regardless of age or education level.
51128pr@reply-direct.com Josh Schultz Kristian Thorland
Biopharmaceutical software and consulting services company Cytel, a portfolio company has acquired MTEK Sciences expanding its real-world analytics (RWA) capabilities. MTEK specialises in methods such as machine learning models and Bayesian optimisation to derive clinical insights from large and complex real- world data (RWD).
“Complex RWD sets are now abundant in the healthcare sector, opening up a wealth of opportunity for pharmaceutical organisations of all sizes,” said Joshua Schultz, Chief Executive Offi cer at Cytel. “Advanced and more sophisticated analytical methods and decision- modelling techniques are needed to harness RWD and turn it into trustworthy evidence. At Cytel, we’re applying our long history of innovative statistical methods to RWD to generate cost-effective insights for our clients and the acquisition of MTEK is another avenue where we are amplifying this approach.”
Ed Mills
Professor Edward Mills, Founding Partner and Director of MTEK, said, “Our experience has shown us that companies need to look beyond the confi nes of traditional analytical approaches if RWD is to positively transform clinical development. In working with Cytel, we’re enhancing our combined ability to develop and deploy the novel solutions needed to confi dently guide companies through this rapidly changing landscape.”
Professor Kristian Thorlund, Founding Partner and Director of MTEK Sciences, added: “Cytel and MTEK have a tightly aligned vision for the future of RWD applications. Combining our comprehensive statistical know-how means we can deliver greater innovation to a wider array of companies as they seek to enrich their drug development process with RWD.”
51124pr@reply-direct.com
To be included in our next issue, send all your News stories to:
heather@intlabmate.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88
